Skip to main content

Articles

Page 2 of 100

  1. Menopausal hormone therapy (MHT) is a risk factor for breast cancer (BC). Evidence suggests that its effect on BC risk could be partly mediated by mammographic density. The aim of this study was to investigate...

    Authors: M. Fornili, V. Perduca, A. Fournier, A. Jérolon, M. C. Boutron-Ruault, G. Maskarinec, G. Severi and L. Baglietto

    Citation: Breast Cancer Research 2021 23:47

    Content type: Research article

    Published on:

  2. Intraoperative radiotherapy with electrons (IOERT) boost could be not inferior to external beam radiotherapy (EBRT) boost in terms of local control and tissue tolerance. The aim of the study is to present the ...

    Authors: Antonella Ciabattoni, Fabiana Gregucci, Gerd Fastner, Silvio Cavuto, Antonio Spera, Stefano Drago, Ingrid Ziegler, Maria Alessandra Mirri, Rita Consorti and Felix Sedlmayer

    Citation: Breast Cancer Research 2021 23:46

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:50

  3. An abundance of tumor-associated macrophages has been shown to be an independent prognostic factor for a poor prognosis of human breast cancer (BC). Adipose tissue accounts for the largest proportion of the br...

    Authors: Lili Lin, Christina Kuhn, Nina Ditsch, Thomas Kolben, Bastian Czogalla, Susanne Beyer, Fabian Trillsch, Elisa Schmoeckel, Doris Mayr, Sven Mahner, Udo Jeschke and Anna Hester

    Citation: Breast Cancer Research 2021 23:45

    Content type: Research article

    Published on:

  4. The epidemiologic evidence from observational studies on breast cancer risk and phthalates, endocrine disrupting chemicals, has been inconsistent. In the only previous study based on pre-diagnostic urinary pht...

    Authors: Anna H. Wu, Adrian A. Franke, Lynne R. Wilkens, Chiuchen Tseng, Shannon M. Conroy, Yuqing Li, Linda M. Polfus, Mindy De Rouen, Christian Caberto, Christopher Haiman, Daniel O. Stram, Loïc Le Marchand and Iona Cheng

    Citation: Breast Cancer Research 2021 23:44

    Content type: Research article

    Published on:

  5. Intraoperative radiotherapy (IORT) is more convenient than standard whole breast external beam radiotherapy (EBRT) as a sole adjuvant radiotherapy for breast cancer. The impact of age on breast cancer course a...

    Authors: Hsin-Yi Yang, Chi-Wen Tu, Chien-Chin Chen, Cheng-Yen Lee and Yu-Chen Hsu

    Citation: Breast Cancer Research 2021 23:43

    Content type: Research article

    Published on:

  6. Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance re...

    Authors: Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha…

    Citation: Breast Cancer Research 2021 23:42

    Content type: Research article

    Published on:

  7. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland III, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu…

    Citation: Breast Cancer Research 2021 23:41

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2017 19:130

  8. Characterization of breast cancer (BC) through the determination of conventional markers such as ER, PR, HER2, and Ki67 has been useful as a predictive and therapeutic tool. Also, assessment of tumor-infiltrat...

    Authors: Gerardo Gatti, Courtney Betts, Darío Rocha, Maribel Nicola, Verónica Grupe, Cecilia Ditada, Nicolas G. Nuñez, Emiliano Roselli, Paula Araya, Jeremías Dutto, Lucia Boffelli, Elmer Fernández, Lisa M. Coussens and Mariana Maccioni

    Citation: Breast Cancer Research 2021 23:40

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:48

  9. Transforming growth factor beta1 (TGFB1) is a multi-functional cytokine that regulates mammary gland development and cancer progression through endocrine, paracrine and autocrine mechanisms. TGFB1 also plays r...

    Authors: Xuan Sun, Sarah M. Bernhardt, Danielle J. Glynn, Leigh J. Hodson, Lucy Woolford, Andreas Evdokiou, Cong Yan, Hong Du, Sarah A. Robertson and Wendy V. Ingman

    Citation: Breast Cancer Research 2021 23:39

    Content type: Research article

    Published on:

  10. Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC ...

    Authors: Francesca Galardi, Francesca De Luca, Chiara Biagioni, Ilenia Migliaccio, Giuseppe Curigliano, Alessandro M. Minisini, Martina Bonechi, Erica Moretti, Emanuela Risi, Amelia McCartney, Matteo Benelli, Dario Romagnoli, Silvia Cappadona, Stefano Gabellini, Cristina Guarducci, Valerio Conti…

    Citation: Breast Cancer Research 2021 23:38

    Content type: Research article

    Published on:

  11. Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versu...

    Authors: Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo and Richard S. Finn

    Citation: Breast Cancer Research 2021 23:37

    Content type: Research article

    Published on:

  12. Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.

    Authors: Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Christopher Herzog, Lale Umutlu, Alex Frydrychowicz, Dorothea Rjosk-Dendorfer, Rachel Würstlein, Ralph Culemann, Christine Eulenburg, Jascha Adams, Henrik Nitzsche, Anna Prange, Sherko Kümmel, Eva-Maria Grischke…

    Citation: Breast Cancer Research 2021 23:36

    Content type: Research article

    Published on:

  13. Brain metastasis of breast cancer exhibits exceedingly poor prognosis, and both triple negative (TN) and Her2+ subtypes have the highest incidence of brain metastasis. Although estrogen blockers are considered to...

    Authors: Shih-Ying Wu, Sambad Sharma, Kerui Wu, Abhishek Tyagi, Dan Zhao, Ravindra Pramod Deshpande and Kounosuke Watabe

    Citation: Breast Cancer Research 2021 23:35

    Content type: Research article

    Published on:

  14. Among women diagnosed with invasive breast cancer, 30% have a prior diagnosis of benign breast disease (BBD). Thus, it is important to identify factors among BBD patients that elevate invasive cancer risk. In ...

    Authors: Jonine D. Figueroa, Gretchen L. Gierach, Máire A. Duggan, Shaoqi Fan, Ruth M. Pfeiffer, Yihong Wang, Roni T. Falk, Olivier Loudig, Mustapha Abubakar, Mindy Ginsberg, Teresa M. Kimes, Kathryn Richert-Boe, Andrew G. Glass and Thomas E. Rohan

    Citation: Breast Cancer Research 2021 23:34

    Content type: Research article

    Published on:

  15. The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in...

    Authors: Iain R. Macpherson, Yaohua He and Carlo Palmieri

    Citation: Breast Cancer Research 2021 23:33

    Content type: Research article

    Published on:

  16. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves

    Citation: Breast Cancer Research 2021 23:32

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:25

  17. Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor...

    Authors: Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon and François-Clément Bidard

    Citation: Breast Cancer Research 2021 23:31

    Content type: Research article

    Published on:

  18. Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclin...

    Authors: Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres and Eddy S. Yang

    Citation: Breast Cancer Research 2021 23:30

    Content type: Research article

    Published on:

  19. MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with c...

    Authors: Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava…

    Citation: Breast Cancer Research 2021 23:29

    Content type: Research article

    Published on:

  20. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf

    Citation: Breast Cancer Research 2021 23:28

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:20

  21. Patients diagnosed with metastatic breast cancer have poor outcome with a median survival of approximately 2 years. While novel therapeutic options are urgently needed, the great majority of breast cancer rese...

    Authors: Jenny Stenström, Ingrid Hedenfalk and Catharina Hagerling

    Citation: Breast Cancer Research 2021 23:27

    Content type: Research article

    Published on:

  22. Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lack...

    Authors: Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch…

    Citation: Breast Cancer Research 2021 23:26

    Content type: Research article

    Published on:

  23. Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of D...

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves

    Citation: Breast Cancer Research 2021 23:25

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:32

  24. Estimates of contralateral breast cancer (CBC) risk in the modern treatment era by year of diagnosis and characteristics of the first breast cancer are needed to assess the impact of recent advances in breast ...

    Authors: Cody Ramin, Diana R. Withrow, Brittny C. Davis Lynn, Gretchen L. Gierach and Amy Berrington de González

    Citation: Breast Cancer Research 2021 23:24

    Content type: Research article

    Published on:

  25. Cyclooxygenase 2 (COX-2) promotes stemness in triple negative breast cancer (TNBC), highlighting COX-2 as a promising therapeutic target in these tumors. However, to date, clinical trials using COX-2 inhibitor...

    Authors: Jun Tian, Vivian Wang, Ni Wang, Baharak Khadang, Julien Boudreault, Khldoun Bakdounes, Suhad Ali and Jean-Jacques Lebrun

    Citation: Breast Cancer Research 2021 23:23

    Content type: Research article

    Published on:

  26. The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have recent...

    Authors: Parichoy Pal Choudhury, Mark N. Brook, Amber N. Hurson, Andrew Lee, Charlotta V. Mulder, Penny Coulson, Minouk J. Schoemaker, Michael E. Jones, Anthony J. Swerdlow, Nilanjan Chatterjee, Antonis C. Antoniou and Montserrat Garcia-Closas

    Citation: Breast Cancer Research 2021 23:22

    Content type: Short report

    Published on:

  27. FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distri...

    Authors: Silvana Mouron, Luis Manso, Eduardo Caleiras, Jose L. Rodriguez-Peralto, Oscar M. Rueda, Carlos Caldas, Ramon Colomer, Miguel Quintela-Fandino and Maria J. Bueno

    Citation: Breast Cancer Research 2021 23:21

    Content type: Research article

    Published on:

  28. Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecula...

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf

    Citation: Breast Cancer Research 2021 23:20

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:28

  29. Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflamm...

    Authors: Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko and Michelle Janelsins

    Citation: Breast Cancer Research 2021 23:19

    Content type: Research article

    Published on:

  30. To evaluate weight change patterns over time following the diagnosis of breast cancer and to examine the association of post-diagnosis weight change and survival outcomes in Black and White patients.

    Authors: Lihua Shang, Masaya Hattori, Gini Fleming, Nora Jaskowiak, Donald Hedeker, Olufunmilayo I. Olopade and Dezheng Huo

    Citation: Breast Cancer Research 2021 23:18

    Content type: Research article

    Published on:

  31. In breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and surv...

    Authors: Anna L. V. Johansson, Cassia B. Trewin, Irma Fredriksson, Kristin V. Reinertsen, Hege Russnes and Giske Ursin

    Citation: Breast Cancer Research 2021 23:17

    Content type: Research article

    Published on:

  32. The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing brea...

    Authors: Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman and Andreas H. Hielscher

    Citation: Breast Cancer Research 2021 23:16

    Content type: Research article

    Published on:

  33. It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune ...

    Authors: Thomas E. Rohan, Rhonda Arthur, Yihong Wang, Sheila Weinmann, Mindy Ginsberg, Sherene Loi and Roberto Salgado

    Citation: Breast Cancer Research 2021 23:15

    Content type: Research article

    Published on:

  34. There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus...

    Authors: Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai and Sarah Mougalian

    Citation: Breast Cancer Research 2021 23:14

    Content type: Research article

    Published on:

  35. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Zaklina Kovacevic, Des R. Richardson, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm…

    Citation: Breast Cancer Research 2021 23:13

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2020 22:75

  36. MicroRNAs have been reported to participate in tumorigenesis, treatment resistance, and tumor metastasis. Novel microRNAs need to be identified and investigated to guide the clinical prognosis or therapy for b...

    Authors: Chong Chen, Yundi Pan, Lipeng Bai, Huilin Chen, Zhaojun Duan, Qin Si, Ruizhe Zhu, Tsung-Hsien Chuang and Yunping Luo

    Citation: Breast Cancer Research 2021 23:12

    Content type: Research article

    Published on:

  37. Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled recep...

    Authors: Xuanmao Jiao, Min Wang, Zhao Zhang, Zhiping Li, Dong Ni, Anthony W. Ashton, Hsin-Yao Tang, David W. Speicher and Richard G. Pestell

    Citation: Breast Cancer Research 2021 23:11

    Content type: Research article

    Published on:

  38. Basal-like breast cancers (BLBCs) are a leading cause of cancer death due to their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a dysfunctional BRCA1. Although most BRCA1-...

    Authors: Feng Bai, Shiqin Liu, Xiong Liu, Daniel P. Hollern, Alexandria Scott, Chuying Wang, Lihan Zhang, Cheng Fan, Li Fu, Charles M. Perou, Wei-Guo Zhu and Xin-Hai Pei

    Citation: Breast Cancer Research 2021 23:10

    Content type: Research article

    Published on:

  39. Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multice...

    Authors: Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi…

    Citation: Breast Cancer Research 2021 23:9

    Content type: Research article

    Published on:

  40. Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xe...

    Authors: Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero…

    Citation: Breast Cancer Research 2021 23:8

    Content type: Research article

    Published on:

  41. Invasive pleomorphic lobular carcinoma (PLC) of the breast is a subtype of invasive lobular cancer which compromises approximately 1% of all epithelial breast malignancies and is characterized by higher nuclea...

    Authors: Gregory M. Riedlinger, Sonali Joshi, Kim M. Hirshfield, Nicola Barnard and Shridar Ganesan

    Citation: Breast Cancer Research 2021 23:7

    Content type: Research article

    Published on:

  42. Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpin...

    Authors: Amy E. McCart Reed, Lauren Kalinowski, Peter T. Simpson and Sunil R. Lakhani

    Citation: Breast Cancer Research 2021 23:6

    Content type: Review

    Published on:

  43. Existence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BC...

    Authors: Yu-Mei Liao, Ya-Hui Wang, Jung-Tung Hung, Yu-Ju Lin, Yen-Lin Huang, Guo-Shiou Liao, Ya-Ling Hsu, Jen-Chien Wu and Alice L. Yu

    Citation: Breast Cancer Research 2021 23:5

    Content type: Research article

    Published on:

  44. NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric ...

    Authors: Karen D. Howarth, Tashfina Mirza, Susanna L. Cooke, Suet-Feung Chin, Jessica C. Pole, Ernest Turro, Matthew D. Eldridge, Raquel Manzano Garcia, Oscar M. Rueda, Chris Boursnell, Jean E. Abraham, Carlos Caldas and Paul A. W. Edwards

    Citation: Breast Cancer Research 2021 23:3

    Content type: Research article

    Published on:

  45. The H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-de...

    Authors: Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond, Walter J. Urba, Maritza Martel, Yaping Wu, Mary Campbell, Zhaoyu Sun, Gary Grunkemeier, Shu Ching Chang, Brady Bernard and David B. Page

    Citation: Breast Cancer Research 2021 23:2

    Content type: Research article

    Published on:

  46. Endocrine therapy resistance is a hallmark of advanced estrogen receptor (ER)-positive breast cancer. In this study, we aimed to determine acquired genomic changes in endocrine-resistant disease.

    Authors: Nolan Priedigkeit, Kai Ding, William Horne, Jay K. Kolls, Tian Du, Peter C. Lucas, Jens-Uwe Blohmer, Carsten Denkert, Anna Machleidt, Barbara Ingold-Heppner, Steffi Oesterreich and Adrian V. Lee

    Citation: Breast Cancer Research 2021 23:1

    Content type: Research article

    Published on:

  47. Tumour-infiltrating lymphocytes (TILs) are of important prognostic and predictive value in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC),...

    Authors: Christine Lundgren, Pär-Ola Bendahl, Maria Ekholm, Mårten Fernö, Carina Forsare, Ute Krüger, Bo Nordenskjöld, Olle Stål and Lisa Rydén

    Citation: Breast Cancer Research 2020 22:140

    Content type: Research article

    Published on:

  48. Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V...

    Authors: Naphannop Sereesongsaeng, Sara H. McDowell, James F. Burrows, Christopher J. Scott and Roberta E. Burden

    Citation: Breast Cancer Research 2020 22:139

    Content type: Research article

    Published on:

  49. Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be associated with breast cancer risk, but previous studies of the association are equivocal and limited by incomplete bl...

    Authors: Gordon P. Watt, Janice Sung, Elizabeth A. Morris, Saundra S. Buys, Angela R. Bradbury, Jennifer D. Brooks, Emily F. Conant, Susan P. Weinstein, Despina Kontos, Meghan Woods, Sarah V. Colonna, Xiaolin Liang, Matthew A. Stein, Malcolm C. Pike and Jonine L. Bernstein

    Citation: Breast Cancer Research 2020 22:138

    Content type: Research article

    Published on:

Annual Journal Metrics